Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.


Rituximab (RTX) therapy is used increasingly to manage myasthenia gravis (MG) patients, and case series have shown particular benefit for those MG patients who have antibodies to muscle-specific kinase (MuSK-MG). We report a MuSK-MG patient with persistent and severe Bcell depletion 3 years after receiving RTX. A 62-year-old woman developed ptosis, bulbar… (More)
DOI: 10.1002/mus.24063


1 Figure or Table

Slides referencing similar topics